Trials / Recruiting
RecruitingNCT07175493
A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
A Phase 1/2 Clinical Study of CM336 Injection in Patients With Relapsed or Refractory Autoimmune Cytopenia
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 158 (estimated)
- Sponsor
- Keymed Biosciences Co.Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of CM336 (BCMA/CD3 Bispecific Antibody) in the treatment of patients with relapsed or refractory autoimmune cytopenia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CM336 Injection | subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol |
Timeline
- Start date
- 2025-11-18
- Primary completion
- 2027-11-18
- Completion
- 2028-11-18
- First posted
- 2025-09-16
- Last updated
- 2025-12-17
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07175493. Inclusion in this directory is not an endorsement.